Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

57.17 -1.73 (-2.95%)
Streaming Delayed Price Updated: 3:34 PM EST, Jan 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 22,077,910
Open 57.79
Bid (Size) 57.17 (600)
Ask (Size) 57.18 (600)
Prev. Close 58.91
Today's Range 56.29 - 57.83
52wk Range 43.08 - 93.80
Shares Outstanding N/A
Dividend Yield 2.04%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Novo Nordisk Stock Dips As Company Faces GLP-1 Antitrust Lawsuit ↗
Novo Nordisk A/S (NYSE:NVO) shares are trading lower on Thursday after the company was hit with a lawsuit from compounding pharmacy Strive Specialties. 
Via Benzinga
Topics Lawsuit
News headline image
Eli Lilly’s $1.2 Billion Acquisition of Ventyx Biosciences: Bridging the Gap Between Weight Loss and Chronic Inflammation
In a bold move to solidify its dominance in the cardiometabolic market, Eli Lilly and Company (NYSE:LLY) announced on January 7, 2026, that it has entered into a definitive agreement to acquire Ventyx... 
Via MarketMinute
Topics Intellectual Property

Performance

YTD
+9.1%
+9.1%
1 Month
+13.5%
+13.5%
3 Month
+0.8%
+0.8%
6 Month
-14.7%
-14.7%
1 Year
-29.6%
-29.6%

More News

Read More
News headline image
Eli Lilly Stock Slips After Antitrust Lawsuit Against GLP-1 Providers ↗
Via Benzinga
Topics Lawsuit
AbbVie Seeks To Grow Obesity Drug Portfolio — Retail Touts Drugmaker As Big Competition To Lilly ↗
Via Stocktwits
VKTX, TERN, GPCR Shares Rally As Novo Nordisk Sounds Willingness Towards Portfolio-Expansion Deals ↗
Via Stocktwits
FDA Clears Popular Weight-Loss Drugs Of Suicide Risk After Review Of Over 100K Patients, Asks Drugmakers To Remove Warnings ↗
Via Stocktwits
Why Is HIMS Stock Slipping Premarket Today? ↗
Via Stocktwits
Slimmer Waistlines, Fatter Margins: Jefferies Says Airline Companies Will Profit From America’s Weight-Loss Boom ↗
Via Stocktwits
News headline image
Healthcare Sector Stages Resilient Rebound as Policy Clarity and GLP-1 Innovations Fuel Investor Optimism
Via MarketMinute
Topics Earnings Economy
News headline image
Is It Time to Dump Your Shares of Eli Lilly? ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Eli Lilly Stock Rallies as Ventyx Deal Calms Wegovy Concerns ↗
Via MarketBeat
News headline image
The Great Recalibration: Why 2026 Could Be Healthcare’s Year to Rebound
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Amgen at the Crossroads: MariTide, Market Volatility, and the Quest for Obesity Dominance
Via PredictStreet
Topics Economy Intellectual Property
News headline image
Eli Lilly vs Novo Nordisk: Which Company Will Dominate the Weight Loss Drug Market in 2026? ↗
Via The Motley Fool
News headline image
Can Novo Nordisk Unseat Eli Lilly as the Weight Loss Drug Leader in 2026? ↗
Via The Motley Fool
News headline image
Why Tempus AI Stock Rose Today ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Beyond the Protein: How AlphaFold 3 Redefined the Blueprint of Life and Accelerated the Drug Discovery Revolution
Via TokenRing AI
Topics Artificial Intelligence
News headline image
Anthropic Launches “Claude for Healthcare”: A Paradigm Shift in Medical AI Integration and HIPAA Security
Via TokenRing AI
Topics Artificial Intelligence
News headline image
From Silicon to Syringes: Nvidia’s AI Dominance Solidified Through Landmark Eli Lilly Alliance
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
The Convergence of Silicon and Science: Eli Lilly and Nvidia Unveil $1 Billion AI Co-Innovation Lab at JPM26
Via MarketMinute
Topics Artificial Intelligence
News headline image
An Investor's Guide to 2026 ↗
Via The Motley Fool
Topics Artificial Intelligence Economy
News headline image
Stocks to Love in 2026 ↗
Via The Motley Fool
Topics ETFs Initial Public Offering
News headline image
This ETF Is Proof That the Healthcare Rebound Is Real ↗
Via MarketBeat
Topics ETFs
News headline image
This Healthcare Stock Could Be One of the Best Companies to Own in 2026 ↗
Via The Motley Fool
News headline image
Eli Lilly Solidifies Immunology Dominance with $1.2 Billion Acquisition of Ventyx Biosciences
Via MarketMinute

Frequently Asked Questions

Is Novo Nordisk A/S Common Stock publicly traded?
Yes, Novo Nordisk A/S Common Stock is publicly traded.
What exchange does Novo Nordisk A/S Common Stock trade on?
Novo Nordisk A/S Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Novo Nordisk A/S Common Stock?
The ticker symbol for Novo Nordisk A/S Common Stock is NVO on the New York Stock Exchange
What is the current price of Novo Nordisk A/S Common Stock?
The current price of Novo Nordisk A/S Common Stock is 57.17
When was Novo Nordisk A/S Common Stock last traded?
The last trade of Novo Nordisk A/S Common Stock was at 01/15/26 03:34 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.